PYMX: Thanks, mcbio, for the CC summary—much appreciated. I remain unconvinced by the business prospects for PMX-60056, notwithstanding the fact that rkrw and biomaven (two of the best biotech investors in these parts) are believers.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”